The fractionated therapy group exhibited significantly lower tumor volumes and did not exceed 200% of the initial tumor volume. 68Ga-labeled sdAbs enabled high-contrast PET imaging and 177Lu-labeled sdAbs, particularly in fractionated regimens, effectively delayed tumor progression and were well tolerated, supporting further clinical translation.

1 month ago

Preclinical • Journal

HER-2 (Human epidermal growth factor receptor 2)

HER-2 positive

Squaric-acid-engineered FAP2286: A next-generation 68Ga/177Lu theranostic ligand with synergistically enhanced affinity, hydrophilicity, and tumor retention. (PubMed, Bioorg Chem)

Squaric acid derivatization synergistically elevates affinity, hydrophilicity, and intratumoral residence while preserving safety, establishing 68Ga/177Lu-FAP2286-SA as a clinically translatable, next-generation theranostic pair for FAP-positive malignancies.

1 month ago

Journal

FAP (Fibroblast activation protein, alpha)

lutetium Lu 177 rofapitide tetraxetan (AAA614)

Prospective pilot study with [89Zr]Zr-girentuximab PET/CT: CA-IX imaging in metastatic triple negative breast cancer (OPALESCENCE). (PubMed, Eur J Nucl Med Mol Imaging)

[89Zr]Zr-girentuximab PET/CT is a sensitive imaging method and offers promise for novel theranostics for mTNBC patients.

1 month ago

Journal

CA9 (Carbonic anhydrase 9)

177Lu-DOTA-girentuximab (TLX250) • Rencarex (girentuximab)

2ms

I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW). (clinicaltrials.gov)

P2, N=120, Completed, Progenics Pharmaceuticals, Inc. | Active, not recruiting --> Completed

2 months ago

Trial completion

Xtandi (enzalutamide) • abiraterone acetate

2ms

A preliminary study on the safety and efficacy of 177Lu-FAP-2286 in gastrointestinal tumours with positive FAP expression. (PubMed, Radiother Oncol)

177Lu-FAP-2286 demonstrated good feasibility and safety in treating FAP-positive gastrointestinal tumors, resulting in disease stabilization in a subset of patients.

2 months ago

Journal

FAP (Fibroblast activation protein, alpha)

lutetium Lu 177 rofapitide tetraxetan (AAA614)

2ms

177Lu-P17-087/177Lu-P17-088 in Patients With Metastatic Castration-resistant Prostate Cancer (clinicaltrials.gov)

P1, N=30, Recruiting, Peking Union Medical College Hospital | Trial completion date: Oct 2023 --> Oct 2026 | Completed --> Recruiting

2 months ago

Enrollment open • Trial completion date

FOLH1 (Folate hydrolase 1)

FOLH1 expression

177Lu-P17-087 • 177Lu-P17-088

2ms

SOLACE: Samarium Optimized for Long-lasting Analgesia in Cancerous End-stage Bone Pain (clinicaltrials.gov)

P1, N=33, Not yet recruiting, Telix Pharmaceuticals (Innovations) Pty Limited

2 months ago

New P1 trial

CycloSam (samarium-153 DOTMP)

2ms

Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 for Metastatic Cancer (clinicaltrials.gov)

P1, N=60, Not yet recruiting, University of Wisconsin, Madison

2 months ago

New P1 trial

90Y-NM600

2ms

LUTEON: Study of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC (clinicaltrials.gov)

P3, N=40, Not yet recruiting, Telix Pharmaceuticals (Innovations) Pty Limited

2 months ago

New P3 trial

177Lu-DOTA-girentuximab (TLX250)

3ms

NeoPSMA: Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC (clinicaltrials.gov)

P1/2, N=228, Not yet recruiting, Novartis Pharmaceuticals | Initiation date: Jun 2025 --> Jun 2026

3 months ago

Trial initiation date

177Lu-PSMA-R2

3ms

67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma (clinicaltrials.gov)

P1/2, N=21, Terminated, Clarity Pharmaceuticals Ltd | Trial primary completion date: Oct 2024 --> Jan 2025

3 months ago

Trial primary completion date

Sartate (67Cu MeCOSar octreotate)